GSK Investigational Site

Kamloops, British Columbia V2C 5T1

0 studies enrolling now · 3 studies all time

What they study most

Asthma, Pulmonary Disease, Chronic Obstructive

Studies at this site

• An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) — Completed
• A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed